STORM target discovery platform and pipeline

At the core of our R&D strategy is a close relationship with our scientific founders at the University of Cambridge. We work hand in hand with their research groups using cutting-edge techniques such as chemical biology, RNA-Seq and RNA mass spectrometry to elucidate the functional role of diverse RNA modifications and identify their protein writers, readers and erasers. We use the latest insights and emerging data from our collaboration to build a unique target discovery platform for the identification of new drug targets.

With our well developed and productive platform, we have established a pipeline of novel, first in class inhibitors with the potential to treat a variety of cancers and other diseases.

SOLD OUT - RNA Epigenetics in Human Disease

A STORM Therapeutics conference | 17-20 September 2019

Find out more


  • Reuven Agami
  • Shankar Balasubramanian
  • Thomas Carell
  • Robert Copeland
  • Tom Cech
  • Michaela Frye
  • Francois Fuks
  • Richard Gregory
  • Chuan He
  • Stacy Horner
  • Samie Jaffrey
  • Narry Kim
  • Jeannie Lee
  • Michal Minczuk
  • Gidi Rechavi
  • Tom Suzuki